Neil J. Greening

Neil J. Greening

Auto-generated profile, based on publicly available information

Neil J. Greening

The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2013 in Thorax
Verified
Journal Article
Open access
PDF file
CBCharlotte E Bolton
Charlotte E Bolton
EBElaine F Bevan-Smith
Elaine F Bevan-Smith
JBJohn D Blakey
John D Blakey
PCPatrick Crowe
Patrick Crowe
SESarah L Elkin
Sarah L Elkin
SWSandy Walmsley
Sandy Walmsley

9 May 2019 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
CBChristopher Brightling
Christopher Brightling
NGNeil Greening
Neil Greening
Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and mortality worldwide, and its prevalence is increasing. Airway inflammation is a consistent feature of COPD and is implicated in the pathogenesis and progression of COPD, but anti-inflammatory therapy is not first-line treatment. The inflammation has many guises and phenotyping this heterogeneity has revealed different patterns. Neutrophil-associated COPD with activation of the inflammasome, T1 and T17 immunity is the most common phenotype with eosinophil-associated T2-mediated immunity in a minority and autoimmunity observed in more severe disease. Biomarkers have enabled targeted anti-inflammatory strategies and revealed that corticosteroids are most effective in those with evidence of eosinophilic inflammation, whereas, in contrast to severe asthma, response to anti-interleukin-5 biologicals in COPD has been disappointing, with smaller benefits for the same intensity of eosinophilic inflammation questioning its role in COPD. Biological therapies beyond T2-mediated inflammation have not demonstrated benefit and in some cases increased risk of infection, suggesting that neutrophilic inflammation and inflammasome activation might be largely driven by bacterial colonisation and dysbiosis. Herein we describe current and future biomarker approaches to assess inflammation in COPD and how this might reveal tractable approaches to precision medicine and unmask important host–environment interactions leading to airway inflammation.

8 July 2014 in BMJ
Verified
Journal Article
Open access
PDF file
NGNeil J Greening
Neil J Greening
JWJ. E. A. Williams
J. E. A. Williams
SHSyed F Hussain
Syed F Hussain
THTheresa C Harvey-Dunstan
Theresa C Harvey-Dunstan
MBM John Bankart
M John Bankart
MSMichael C Steiner
Michael C Steiner
Objective To investigate whether an early rehabilitation intervention initiated during acute admission for exacerbations of chronic respiratory disease reduces the risk of readmission over 12 months and ameliorates the negative effects of the episode on physical performance and health status. Design Prospective, randomised controlled trial. Setting An acute cardiorespiratory unit in a teaching hospital and an acute medical unit in an affiliated teaching district general hospital, United Kingdom. Participants 389 patients aged between 45 and 93 who within 48 hours of admission to hospital with an exacerbation of chronic respiratory disease were randomised to an early rehabilitation intervention (n=196) or to usual care (n=193). Main outcome measures The primary outcome was readmission rate at 12 months. Secondary outcomes included number of hospital days, mortality, physical performance, and health status. The primary analysis was by intention to treat, with prespecified per protocol analysis as a secondary outcome. Interventions Participants in the early rehabilitation group received a six week intervention, started within 48 hours of admission. The intervention comprised prescribed, progressive aerobic, resistance, and neuromuscular electrical stimulation training. Patients also received a self management and education package. Results Of the 389 participants, 320 (82%) had a primary diagnosis of chronic obstructive pulmonary disease. 233 (60%) were readmitted at least once in the following year (62% in the intervention group and 58% in the control group). No significant difference between groups was found (hazard ratio 1.1, 95% confidence interval 0.86 to 1.43, P=0.4). An increase in mortality was seen in the intervention group at one year (odds ratio 1.74, 95% confidence interval 1.05 to 2.88, P=0.03). Significant recovery in physical performance and health status was seen after discharge in both groups, with no significant difference between groups at one year. Conclusion Early rehabilitation during hospital admission for chronic respiratory disease did not reduce the risk of subsequent readmission or enhance recovery of physical function following the event over 12 months. Mortality at 12 months was higher in the intervention group. The results suggest that beyond current standard physiotherapy practice, progressive exercise rehabilitation should not be started during the early stages of the acute illness. Trial registration Current Controlled Trials ISRCTN05557928.

1 August 2016 in Chest
Verified
Journal Article
Closed access
MBMona Bafadhel
Mona Bafadhel
NGNeil J. Greening
Neil J. Greening
THTheresa C. Harvey-Dunstan
Theresa C. Harvey-Dunstan
JWJohanna E.A. Williams
Johanna E.A. Williams
MMMichael D. Morgan
Michael D. Morgan
MSMichael C. Steiner
Michael C. Steiner

8 April 2024 in Nature Immunology
Verified
Journal Article
Open access
PDF file
FLFelicity Liew
Felicity Liew
CEClaudia Efstathiou
Claudia Efstathiou
SFSara Fontanella
Sara Fontanella
MRMatthew Richardson
Matthew Richardson
RSRuth Saunders
Ruth Saunders
POPeter JM Openshaw
Peter JM Openshaw
One in ten severe acute respiratory syndrome coronavirus 2 infections result in prolonged symptoms termed long coronavirus disease (COVID), yet disease phenotypes and mechanisms are poorly understood1. Here we profiled 368 plasma proteins in 657 participants ≥3 months following hospitalization. Of these, 426 had at least one long COVID symptom and 233 had fully recovered. Elevated markers of myeloid inflammation and complement activation were associated with long COVID. IL-1R2, MATN2 and COLEC12 were associated with cardiorespiratory symptoms, fatigue and anxiety/depression; MATN2, CSF3 and C1QA were elevated in gastrointestinal symptoms and C1QA was elevated in cognitive impairment. Additional markers of alterations in nerve tissue repair (SPON-1 and NFASC) were elevated in those with cognitive impairment and SCG3, suggestive of brain–gut axis disturbance, was elevated in gastrointestinal symptoms. Severe acute respiratory syndrome coronavirus 2-specific immunoglobulin G (IgG) was persistently elevated in some individuals with long COVID, but virus was not detected in sputum. Analysis of inflammatory markers in nasal fluids showed no association with symptoms. Our study aimed to understand inflammatory processes that underlie long COVID and was not designed for biomarker discovery. Our findings suggest that specific inflammatory pathways related to tissue damage are implicated in subtypes of long COVID, which might be targeted in future therapeutic trials.

1 October 2023 in Thorax
Verified
Journal Article
Closed access
PDF file
WMWilliam Man
William Man
ECEmma Chaplin
Emma Chaplin
EDEnya Daynes
Enya Daynes
ADAlistair Drummond
Alistair Drummond
RERachael A Evans
Rachael A Evans
SSSally J Singh
Sally J Singh
Since the Guideline, there is deeper understanding of referral characteristics, outcome measures, patient selection, programme delivery, potential adjuncts and the role of maintenance following PR. The BTS Clinical Statement on PR is a narrative review which provides a snapshot of current knowledge and best practice in topical areas by providing a series of clinical practice points that are informed by evidence where this exists, or based on expert opinion and collective clinical experience where evidence is limited.